ArticleBMC oral health2026
Salivary opiorphin as a potential non-invasive biomarker for dental anxiety.
Article in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundDental anxiety remains a major challenge in clinical dentistry, often preventing patients from seeking necessary treatment and compromising oral health outcomes. Although psychological scales such as Corah's Dental Anxiety Scale are widely used to assess anxiety, objective biochemical markers could provide valuable complementary information. Opiorphin, an endogenous peptide known for its analgesic and antidepressant-like effects, has recently emerged as a potential biomarker for stress and pain regulation. However, the role of Opiorphin in dental anxiety remains largely unexplored; therefore, to the best of our knowledge, the present investigation represents an initial effort to address this gap in the literature. This study aimed to estimate salivary opiorphin levels in patients undergoing routine dental checkups and examine their correlation with anxiety levels using Corah's Dental Anxiety Scale. Additionally, it sought to evaluate the relationship between salivary opiorphin and the established dental anxiety biomarker, salivary alpha-amylase.
methodsFifty-six adult participants aged 20-60 years who reported for routine dental checkups without associated pain, systemic illness, or recent analgesic use were enrolled. Corah's Dental Anxiety Scale was used to evaluate anxiety, and unstimulated saliva samples were collected. Opiorphin levels were quantified using a human opiorphin ELISA kit, while salivary alpha-amylase activity was determined using a human AMY1 ELISA kit.
resultsA strong, statistically significant positive correlation was found between anxiety scores and salivary opiorphin levels, whereas no significant relationship was observed with salivary alpha-amylase.
conclusionThese findings indicate that salivary opiorphin may serve as a novel, non-invasive biomarker for dental anxiety, offering new avenues for early detection and individualized management of anxious patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.